Difficulty: Medium
Average Score: 94%
Practice
Prophylactic tamoxifen in woman at high risk of breast cancer results in:
Correct answer
A
Rationale
Prophylactic tamoxifen in women at high risk of breast cancer results in the blockade of estrogen receptors in breast tissue (Option A) because tamoxifen is a selective estrogen receptor modulator (SERM) that competes with estrogen for binding to the estrogen receptors in breast tissue. By blocking these receptors, tamoxifen helps reduce the stimulatory effects of estrogen on breast tissue, thereby lowering the risk of developing breast cancer.
Option B is incorrect because tamoxifen primarily acts on estrogen receptors in breast tissue, not in the hypothalamus. The hypothalamus is involved in regulating hormonal signaling but is not the target of tamoxifen therapy.
Option C is incorrect because tamoxifen is actually associated with a decreased risk of osteoporosis due to its estrogen-like effects on bone density. Estrogen is known to have a protective effect on bone health, and tamoxifen, by partially mimicking estrogen's actions, can help maintain bone density in postmenopausal women.
Option D is incorrect because tamoxifen use is associated with an increased risk of endometrial carcinoma, not a decreased incidence. This is due to the estrogenic effects of tamoxifen on the endometrium, which can lead to hyperplasia and an increased risk of developing endometrial cancer.
In an educational context, understanding the mechanism of action and potential side effects of chemotherapy drugs like tamoxifen is crucial for healthcare professionals involved in cancer care. This knowledge helps in making informed decisions regarding treatment options and managing potential side effects effectively, ultimately improving patient outcomes.
Option B is incorrect because tamoxifen primarily acts on estrogen receptors in breast tissue, not in the hypothalamus. The hypothalamus is involved in regulating hormonal signaling but is not the target of tamoxifen therapy.
Option C is incorrect because tamoxifen is actually associated with a decreased risk of osteoporosis due to its estrogen-like effects on bone density. Estrogen is known to have a protective effect on bone health, and tamoxifen, by partially mimicking estrogen's actions, can help maintain bone density in postmenopausal women.
Option D is incorrect because tamoxifen use is associated with an increased risk of endometrial carcinoma, not a decreased incidence. This is due to the estrogenic effects of tamoxifen on the endometrium, which can lead to hyperplasia and an increased risk of developing endometrial cancer.
In an educational context, understanding the mechanism of action and potential side effects of chemotherapy drugs like tamoxifen is crucial for healthcare professionals involved in cancer care. This knowledge helps in making informed decisions regarding treatment options and managing potential side effects effectively, ultimately improving patient outcomes.